{
    "id": 18945,
    "fullName": "RHEB Q64L",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "RHEB Q64L does not lie within any known functional domains of the Rheb protein (UniProt.org). Q64L results in a loss of Rheb GTPase activity as indicated by increased GTP-bound Rheb, but remains sensitive to GAP stimulation, leads to activation of mTOR signaling and transformation of cultured cells (PMID: 18521078, PMID: 15340059, PMID: 12869586).",
            "references": [
                {
                    "id": 4750,
                    "pubMedId": 15340059,
                    "title": "Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15340059"
                },
                {
                    "id": 18003,
                    "pubMedId": 18521078,
                    "title": "Constitutively active Rheb induces oncogenic transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18521078"
                },
                {
                    "id": 4751,
                    "pubMedId": 12869586,
                    "title": "Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12869586"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6009,
        "geneSymbol": "RHEB",
        "terms": [
            "RHEB",
            "RHEB2"
        ]
    },
    "variant": "Q64L",
    "createDate": "03/01/2016",
    "updateDate": "03/03/2020",
    "referenceTranscriptCoordinates": {
        "id": 152400,
        "transcript": "NM_005614",
        "gDna": "chr7:g.151484738T>A",
        "cDna": "c.191A>T",
        "protein": "p.Q64L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4852,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lymphoma cells overexpressing RHEB Q64L demonstrated reduced sensitivity to Adriamycin (doxorubicin) treatment in cell line xenograft models (PMID: 18708578).",
            "molecularProfile": {
                "id": 19340,
                "profileName": "RHEB Q64L"
            },
            "therapy": {
                "id": 1009,
                "therapyName": "Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4855,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) and Adriamycin (doxorubicin) combination treatment resulted in improved survival and prolonged remission in cell line xenograft animal models of lymphoma overexpressing RHEB Q64L (PMID: 18708578).",
            "molecularProfile": {
                "id": 19340,
                "profileName": "RHEB Q64L"
            },
            "therapy": {
                "id": 3663,
                "therapyName": "Doxorubicin + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4857,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment inhibited mTORC1 activation in lymphoma cell lines overexpressing RHEB Q64L (PMID: 18708578).",
            "molecularProfile": {
                "id": 19340,
                "profileName": "RHEB Q64L"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4854,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) treatment did not improve survival in cell line xenograft animal models of lymphoma over expressing RHEB Q64L (PMID: 18708578).",
            "molecularProfile": {
                "id": 19340,
                "profileName": "RHEB Q64L"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4858,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment did not inhibit mTORC1 activation in lymphoma cell lines overexpressing RHEB Q64L and RHEB M184L (PMID: 18708578).",
            "molecularProfile": {
                "id": 19342,
                "profileName": "RHEB Q64L RHEB M184L"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4861,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment inhibited proliferation of lymphoma cell lines harboring MYC amplification, PTEN deficiency, and overexpressing RHEB Q64L in culture (PMID: 18708578).",
            "molecularProfile": {
                "id": 19400,
                "profileName": "MYC amp PTEN dec exp RHEB Q64L"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4862,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment did not inhibit proliferation of lymphoma cell lines harboring MYC amplification, PTEN deficiency, and overexpressing RHEB Q64L and RHEB M184L in culture (PMID: 18708578).",
            "molecularProfile": {
                "id": 19401,
                "profileName": "MYC amp PTEN dec exp RHEB Q64L RHEB M184L"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4864,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment inhibited proliferation of lymphoma cell lines harboring MYC amplification, ARF deletion, and overexpressing RHEB Q64L and RHEB M184L in culture (PMID: 18708578).",
            "molecularProfile": {
                "id": 19403,
                "profileName": "ARF1 del MYC amp RHEB Q64L RHEB M184L"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 19340,
            "profileName": "RHEB Q64L",
            "profileTreatmentApproaches": [
                {
                    "id": 7922,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "RHEB Q64L"
                }
            ]
        },
        {
            "id": 19342,
            "profileName": "RHEB Q64L RHEB M184L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19400,
            "profileName": "MYC amp PTEN dec exp RHEB Q64L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19401,
            "profileName": "MYC amp PTEN dec exp RHEB Q64L RHEB M184L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19403,
            "profileName": "ARF1 del MYC amp RHEB Q64L RHEB M184L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 152400,
            "transcript": "NM_005614",
            "gDna": "chr7:g.151484738T>A",
            "cDna": "c.191A>T",
            "protein": "p.Q64L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}